{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:22:35Z","timestamp":1790241755220,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T00:00:00Z","timestamp":1437004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10620-015-3796-4","type":"journal-article","created":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T11:05:11Z","timestamp":1436958311000},"page":"3743-3755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn\u2019s Disease"],"prefix":"10.1007","volume":"60","author":[{"given":"Philip N.","family":"Okafor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetoro T.","family":"Okafor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Erim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,16]]},"reference":[{"key":"3796_CR1","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1001\/jama.286.19.2450","volume":"286","author":"JA Kovacs","year":"2001","unstructured":"Kovacs JA, Gill VJ, Meshnick S, et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA. 2001;286:2450\u20132460.","journal-title":"JAMA"},{"key":"3796_CR2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3201\/eid0809.020096","volume":"8","author":"JR Stringer","year":"2002","unstructured":"Stringer JR, Beard CB, Miller RF, et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002;8:891\u2013896.","journal-title":"Emerg Infect Dis"},{"key":"3796_CR3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3109\/s10165-008-0037-0","volume":"18","author":"S Mori","year":"2008","unstructured":"Mori S, Cho I, Ichiyasu H, et al. Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: a possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy. Mod Rheumatol. 2008;18:240\u2013246.","journal-title":"Mod Rheumatol"},{"key":"3796_CR4","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q","volume":"43","author":"JB Chung","year":"2000","unstructured":"Chung JB, Armstrong K, Schwartz JS, et al. Cost effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener\u2019s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 2000;43:1841\u20131848.","journal-title":"Arthritis Rheum"},{"key":"3796_CR5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/acr.20435","volume":"63","author":"TA Kermani","year":"2011","unstructured":"Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series. Arthritis Care Res. 2011;63:761\u2013765.","journal-title":"Arthritis Care Res"},{"key":"3796_CR6","first-page":"1191","volume":"19","author":"A Porges","year":"1992","unstructured":"Porges A, Beattie S, Ritchlin C, et al. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol. 1992;19:1191\u20131194.","journal-title":"J Rheumatol"},{"key":"3796_CR7","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","volume":"42","author":"MM Ward","year":"1999","unstructured":"Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42:780\u2013789.","journal-title":"Arthritis Rheum"},{"key":"3796_CR8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1378\/chest.128.2.573","volume":"128","author":"E Festic","year":"2005","unstructured":"Festic E, Gajic O, Limper AH, et al. Acute respiratory failure due to Pneumocystis pneumonia in patients without human immunodeficiency virus infection outcome and associated features. CHEST J. 2005;128:573\u2013579.","journal-title":"CHEST J"},{"issue":"1","key":"3796_CR9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.12-0477","volume":"144","author":"I Martin-Garrido","year":"2013","unstructured":"Martin-Garrido I, Carmona EM, Specks U, et al. Pneumocystis pneumonia in patients treated with rituximab. CHEST J. 2013;144:258\u2013265.","journal-title":"CHEST J"},{"key":"3796_CR10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1399-3062.2012.00739.x","volume":"14","author":"J McKinnell","year":"2012","unstructured":"McKinnell J, Cannella A, Kunz D, et al. Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. Trans Infect Dis. 2012;14:510\u2013518.","journal-title":"Trans Infect Dis"},{"key":"3796_CR11","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1128\/AAC.00669-11","volume":"55","author":"SM Moon","year":"2011","unstructured":"Moon SM, Kim T, Sung H, et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother. 2011;55:4613\u20134618.","journal-title":"Antimicrob Agents Chemother"},{"key":"3796_CR12","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","volume":"350","author":"CF Thomas Jr","year":"2004","unstructured":"Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487\u20132498.","journal-title":"N Engl J Med"},{"key":"3796_CR13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archinte.162.8.921","volume":"162","author":"SJ Goldie","year":"2002","unstructured":"Goldie SJ, Kaplan JE, Losina E, et al. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002;162:921.","journal-title":"Arch Intern Med"},{"key":"3796_CR14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/MIB.0b013e3182802a9b","volume":"19","author":"MD Long","year":"2013","unstructured":"Long MD, Farraye FA, Okafor PN, et al. Increased risk of Pneumocystis Jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1018\u20131024.","journal-title":"Inflamm Bowel Dis"},{"key":"3796_CR15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00054725-200407000-00017","volume":"10","author":"M Seddik","year":"2004","unstructured":"Seddik M, Meliez H, Seguy D, et al. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn\u2019s disease. Inflamm Bowel Dis. 2004;10:436\u2013437.","journal-title":"Inflamm Bowel Dis"},{"key":"3796_CR16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00054725-200409000-00025","volume":"10","author":"FS Velayos","year":"2004","unstructured":"Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti\u2013tumor necrosis factor-\u03b1 therapy with infliximab for Crohn\u2019s disease. Inflamm Bowel Dis. 2004;10:657\u2013660.","journal-title":"Inflamm Bowel Dis"},{"key":"3796_CR17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ibd.20261","volume":"14","author":"DM Poppers","year":"2008","unstructured":"Poppers DM, Scherl EJ. Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care. Inflamm Bowel Dis. 2008;14:106\u2013113.","journal-title":"Inflamm Bowel Dis"},{"key":"3796_CR18","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1097\/MIB.0b013e318281f562","volume":"19","author":"PN Okafor","year":"2013","unstructured":"Okafor PN, Nunes DP, Farraye FA. Pneumocystis jiroveci pneumonia in inflammatory bowel disease: When should prophylaxis be considered? Inflamm Bowel Dis. 2013;19:1764\u20131771.","journal-title":"Inflamm Bowel Dis"},{"key":"3796_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","volume":"3","author":"J-F Rahier","year":"2009","unstructured":"Rahier J-F, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn\u2019s Colitis. 2009;3:47\u201391.","journal-title":"J Crohn\u2019s Colitis"},{"key":"3796_CR20","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-Effectiveness in Health and Medicine","author":"MR Gold","year":"1996","unstructured":"Gold MR. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996."},{"key":"3796_CR21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0168-8510(99)00007-X","volume":"47","author":"J Mason","year":"1999","unstructured":"Mason J, Eccles M, Freemantle N, et al. A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines. Health Policy. 1999;47:37\u201352.","journal-title":"Health Policy"},{"key":"3796_CR22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","volume":"276","author":"MC Weinstein","year":"1996","unstructured":"Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253\u20131258.","journal-title":"JAMA"},{"key":"3796_CR23","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"AH Briggs","year":"2006","unstructured":"Briggs AH, Claxton K, Sculpher MJ. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006."},{"key":"3796_CR24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","volume":"104","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2009;104:465\u2013483.","journal-title":"Am J Gastroenterol"},{"key":"3796_CR25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2036.2010.04356.x","volume":"32","author":"D Malone","year":"2010","unstructured":"Malone D, Waters H, Van Den Bos J, et al. A claims-based Markov model for Crohn\u2019s disease. Aliment Pharmacol Ther. 2010;32:448\u2013458.","journal-title":"Aliment Pharmacol Ther"},{"key":"3796_CR26","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1097\/01.MIB.0000435850.17263.13","volume":"19","author":"PN Okafor","year":"2013","unstructured":"Okafor PN, Stallwood CG, Nguyen L, et al. Cost-effectiveness of nonmelanoma skin cancer screening in Crohn\u2019s disease patients. Inflamm Bowel Dis. 2013;19:2787\u20132795.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"3796_CR27","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcrc.2013.12.005","volume":"29","author":"Y Ko","year":"2014","unstructured":"Ko Y, Jeong B-H, Park HY, et al. Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients. J Crit Care. 2014;29:356\u2013361.","journal-title":"J Crit Care"},{"key":"3796_CR28","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/jac\/dkp372","volume":"64","author":"J Helweg-Larsen","year":"2009","unstructured":"Helweg-Larsen J, Benfield T, Atzori C, et al. Clinical efficacy of first-and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother. 2009;64:1282\u20131290.","journal-title":"J Antimicrob Chemother"},{"key":"3796_CR29","doi-asserted-by":"crossref","unstructured":"Gilroy SA, Bennett NJ. Pneumocystis pneumonia. In: Seminars in respiratory and critical care medicine; 2011. \u00a9Thieme Medical Publishers; 2011, pp. 775\u2013782.","DOI":"10.1055\/s-0031-1295725"},{"key":"3796_CR30","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255\u20131259.","journal-title":"Lancet"},{"key":"3796_CR31","first-page":"1781","volume":"68","author":"MA Riedl","year":"2003","unstructured":"Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68:1781\u20131790.","journal-title":"Am Fam Physician"},{"key":"3796_CR32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","volume":"4","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry. Clinl Gastroenterol Hepatol. 2006;4:621\u2013630.","journal-title":"Clinl Gastroenterol Hepatol"},{"key":"3796_CR33","unstructured":"Arias E. United States life tables, 2008. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 2012;61:1\u201363."},{"key":"3796_CR34","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","volume":"139","author":"KT Thia","year":"2010","unstructured":"Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn\u2019s disease in a population-based cohort. Gastroenterology. 2010;139:1147\u20131155.","journal-title":"Gastroenterology"},{"key":"3796_CR35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","volume":"371","author":"MD Cappellini","year":"2008","unstructured":"Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64\u201374.","journal-title":"Lancet"},{"key":"3796_CR36","unstructured":"American Hospital Association. Underpayment by Medicare and Medicaid Fact Sheet. Chicago, IL: American Hospital Association; 2010."},{"key":"3796_CR37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2036.2007.03576.x","volume":"27","author":"S Gunesh","year":"2008","unstructured":"Gunesh S, Thomas G, Williams G, et al. The incidence of Crohn\u2019s disease in Cardiff over the last 75\u00a0years: an update for 1996\u20132005. Aliment Pharmacol Ther. 2008;27:211\u2013219.","journal-title":"Aliment Pharmacol Ther"},{"key":"3796_CR38","doi-asserted-by":"crossref","first-page":"e23158","DOI":"10.1371\/journal.pone.0023158","volume":"6","author":"JR Harris","year":"2011","unstructured":"Harris JR, Marston BJ, Sangrujee N, et al. Cost-effectiveness analysis of diagnostic options for Pneumocystis pneumonia (PCP). PloS One. 2011;6:e23158.","journal-title":"PloS One"},{"key":"3796_CR39","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1086\/379071","volume":"37","author":"RC LaRocque","year":"2003","unstructured":"LaRocque RC, Katz JT, Perruzzi P, et al. The utility of sputum induction for diagnosis of Pneumocystis pneumonia in immunocompromised patients without human immunodeficiency virus. Clin Infect Dis. 2003;37:1380\u20131383.","journal-title":"Clin Infect Dis"},{"key":"3796_CR40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1023\/A:1015570104121","volume":"24","author":"H Beijer","year":"2002","unstructured":"Beijer H, De Blaey C. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24:46\u201354.","journal-title":"Pharm World Sci"},{"key":"3796_CR41","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/gerona\/61.5.511","volume":"61","author":"JT Hanlon","year":"2006","unstructured":"Hanlon JT, Pieper CF, Hajjar ER, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol Ser A. 2006;61:511\u2013515.","journal-title":"J Gerontol Ser A"},{"key":"3796_CR42","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar4472","volume":"16","author":"T Katsuyama","year":"2014","unstructured":"Katsuyama T, Saito K, Kubo S, et al. Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther. 2014;16:R43.","journal-title":"Arthritis Res Ther"},{"key":"3796_CR43","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/thorax.58.7.594","volume":"58","author":"N Maskell","year":"2003","unstructured":"Maskell N, Waine D, Lindley A, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax. 2003;58:594\u2013597.","journal-title":"Thorax"},{"key":"3796_CR44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ibd.20261","volume":"14","author":"DM Poppers","year":"2008","unstructured":"Poppers DM, Scherl EJ. Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care. Inflamm Bowel Dis. 2008;14:106\u2013113.","journal-title":"Inflamm Bowel Dis"},{"key":"3796_CR45","doi-asserted-by":"crossref","unstructured":"Baudet A, Rahmi G, Bretagne A-L, et al. Severe ulcerative colitis: present medical treatment strategies. 2008;447\u2013457.","DOI":"10.1517\/14656566.9.3.447"},{"key":"3796_CR46","doi-asserted-by":"crossref","unstructured":"Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. In: Mayo Clinic Proceedings, vol. 82. Elsevier; 2007. pp. 1052\u20131059.","DOI":"10.4065\/82.9.1052"},{"key":"3796_CR47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archinte.1996.00440020081010","volume":"156","author":"J Ioannidis","year":"1996","unstructured":"Ioannidis J, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177.","journal-title":"Arch Intern Med"},{"key":"3796_CR48","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","volume":"339","author":"WM El-Sadr","year":"1998","unstructured":"El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med. 1998;339:1889\u20131895.","journal-title":"N Engl J Med"},{"key":"3796_CR49","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/clinids\/23.4.718","volume":"23","author":"BA Barber","year":"1996","unstructured":"Barber BA, Pegram PS, High KP. Clindamycin\/primaquine as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis. 1996;23:718\u2013722.","journal-title":"Clin Infect Dis"},{"key":"3796_CR50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1378\/chest.110.1.136","volume":"110","author":"K-T Yeung","year":"1996","unstructured":"Yeung K-T, Chan M, Chan CK. The safety of iv pentamidine administered in an ambulatory setting. CHEST J. 1996;110:136\u2013140.","journal-title":"CHEST J"},{"key":"3796_CR51","unstructured":"Castro JG, Morrison-Bryant M. Management of Pneumocystis jirovecii pneumonia in HIV infected patients: current options, challenges and future directions. HIV\/AIDS (Auckland, NZ) 2009;2:123\u2013134."},{"key":"3796_CR52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.7205\/MILMED.171.9.905","volume":"171","author":"CK Murray","year":"2006","unstructured":"Murray CK, Chinevere TD, Grant E, et al. Prevalence of glucose-6-phosphate dehydrogenase deficiency in US Army personnel. Mil Med. 2006;171:905\u2013907.","journal-title":"Mil Med"},{"key":"3796_CR53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00054725-199712000-00004","volume":"3","author":"JC Gregor","year":"1997","unstructured":"Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn\u2019s disease. Inflamm Bowel Dis. 1997;3:265\u2013276.","journal-title":"Inflamm Bowel Dis"},{"key":"3796_CR54","doi-asserted-by":"crossref","unstructured":"Obasaju C, Bowman L, Wang P, et al. Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN). Ann Oncol. 2013;mdt123.","DOI":"10.1093\/annonc\/mdt123"},{"key":"3796_CR55","doi-asserted-by":"crossref","unstructured":"Onukwugha E, Yong C, Hussain A, et al. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer. BMC Medical Research Methodology. 2014;14:1.","DOI":"10.1186\/1471-2288-14-1"},{"key":"3796_CR56","doi-asserted-by":"crossref","unstructured":"Hoover DR, Crystal S, Kumar R, et al. Medical expenditures during the last year of life: findings from the 1992\u20131996 Medicare current beneficiary survey. Health Serv Res. 2002;37:1625\u20131642.","DOI":"10.1111\/1475-6773.01113"},{"key":"3796_CR57","doi-asserted-by":"crossref","unstructured":"Bond C, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006;26:601\u2013608.","DOI":"10.1592\/phco.26.5.601"},{"key":"3796_CR58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0016-5085(99)70549-4","volume":"117","author":"MD Silverstein","year":"1999","unstructured":"Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn\u2019s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49\u201357.","journal-title":"Gastroenterology"},{"key":"3796_CR59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2036.1999.00437.x","volume":"13","author":"F Ward","year":"1999","unstructured":"Ward F, Bodger K, Daly M, et al. Clinical economics review: medical management of inflammatory bowel disease. Aliment Pharmacol Ther. 1999;13:15\u201326.","journal-title":"Aliment Pharmacol Ther"},{"key":"3796_CR60","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/00004836-199206000-00010","volume":"14","author":"AR Hay","year":"1992","unstructured":"Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol. 1992;14:318\u2013327.","journal-title":"J Clin Gastroenterol"},{"key":"3796_CR61","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S1542-3565(10)00740-8","volume":"8","author":"BG Levesque","year":"2010","unstructured":"Levesque BG, Cipriano LE, Chang SL, et al. Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2010;8:e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3796_CR62","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/gut.2005.079350","volume":"55","author":"T Jess","year":"2006","unstructured":"Jess T, Loftus E, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940\u20132004. Gut. 2006;55:1248\u20131254.","journal-title":"Gut"},{"key":"3796_CR63","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1053\/gast.1996.v110.pm8613037","volume":"110","author":"P Persson","year":"1996","unstructured":"Persson P, Bernell O, Leijonmarck CE, et al. Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 1996;110:1339\u20131345.","journal-title":"Gastroenterology"},{"key":"3796_CR64","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2036.2007.03276.x","volume":"25","author":"C Canavan","year":"2007","unstructured":"Canavan C, Abrams K, Mayberry J. Meta-analysis: mortality in Crohn\u2019s disease. Aliment Pharmacol Ther. 2007;25:861\u2013870.","journal-title":"Aliment Pharmacol Ther"},{"key":"3796_CR65","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1017\/S0266462304001084","volume":"20","author":"I Jaisson-Hot","year":"2004","unstructured":"Jaisson-Hot I, Flouri\u00e9 B, Descos L, et al. Management for severe Crohn\u2019s disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care. 2004;20:274\u2013279.","journal-title":"Int J Technol Assess Health Care"},{"key":"3796_CR66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","volume":"30","author":"K Bodger","year":"2009","unstructured":"Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn\u2019s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30:265\u2013274.","journal-title":"Aliment Pharmacol Ther"},{"key":"3796_CR67","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/aje\/126.2.310","volume":"126","author":"R Kaslow","year":"1987","unstructured":"Kaslow R, Ostrow D, Detels R, et al. The Multicenter AIDS Cohort study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310\u2013318.","journal-title":"Am J Epidemiol"},{"key":"3796_CR68","unstructured":"MACS. Multicenter AIDS Cohort Study (MACS) Public Dataset: Release PO4. Springfield, VA: National Technical Information Service 1995."},{"issue":"2014","key":"3796_CR69","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/imj.12599","volume":"44.12b","author":"L Cooley","year":"2014","unstructured":"Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies. Int Med J. 2014;44:1350\u20131363.","journal-title":"Int Med J"},{"key":"3796_CR70","doi-asserted-by":"crossref","unstructured":"Jiang X, Mei X, Feng D, et al. \u201cProphylaxis and treatment of Pneumocystis jiroveci pneumonia in lymphoma patients subjected to Rituximab-contained therapy: a systemic review and meta-analysis.\u201d (2015):e0122171.","DOI":"10.1371\/journal.pone.0122171"},{"key":"3796_CR71","doi-asserted-by":"crossref","unstructured":"Fill\u00e2tre P, Decaux O, Jouneau S, et al. \u201cIncidence of Pneumocystis jiroveci Pneumonia among groups at risk in HIV-negative patients.\u201d\u00a0Am J Med. 2014;127:1242-e11.","DOI":"10.1016\/j.amjmed.2014.07.010"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-015-3796-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3796-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:14:47Z","timestamp":1717978487000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-015-3796-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,16]]},"references-count":71,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["3796"],"URL":"https:\/\/doi.org\/10.1007\/s10620-015-3796-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,16]]}}}